Actinogen Medical Ltd (ASX:ACW)
A$ 0.027 0.001 (3.85%) Market Cap: 83.23 Mil Enterprise Value: 74.10 Mil PE Ratio: 0 PB Ratio: 3.86 GF Score: 0/100

Actinogen Medical Ltd at Biotechnology Industry Organization (BIO) International Convention (Virtual) Transcript

Jun 08, 2020 - Jun 12, 2020 / NTS GMT
Bill Ketelbey
Actinogen Medical Limited - CEO & MD

My name is Bill Ketelbey, CEO of Actinogen Medical, an ASX listed biotech company developing innovative treatments for the cognitive impairment associated with various neurological and metabolic diseases due to raised cortisol, and this includes Alzheimer's disease. There is now substantial literature to demonstrate that chronically raised, persistently raised cortisol is associated with cognitive impairment across a number of clinical conditions.

And our lead compound, Xanamem, has been specifically designed to inhibit cortisol production in the brain. It does this through the inhibition of the [11beta-HSD1] enzyme intracellularly. We've got good proof of concept data demonstrated from our animal trials, and again, from our human trials, and equally, a good strong safety profile has been demonstrated across our Phase 1 and Phase 2 studies.

We've dosed over 200 patients with our drug, with Xanamem, to date. We equally have shown an excellent PK/PD profile for our drug, so we can now show that Xanamem is an efficacious

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot